CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition.

MLA

Nasser, Ali M., et al. “CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 30, no. 14, July 2024, pp. 2996–3005. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-24-0562.

APA

Nasser, A. M., Melamed, L., Wetzel, E. A., Chang, J. C.-C., Nagashima, H., Kitagawa, Y., Muzyka, L., Wakimoto, H., Cahill, D. P., & Miller, J. J. (2024). CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 30(14), 2996–3005. https://doi.org/10.1158/1078-0432.CCR-24-0562

Chicago

Nasser, Ali M, Lisa Melamed, Ethan A Wetzel, Jenny Chia-Chen Chang, Hiroaki Nagashima, Yosuke Kitagawa, Logan Muzyka, Hiroaki Wakimoto, Daniel P Cahill, and Julie J Miller. 2024. “CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 30 (14): 2996–3005. doi:10.1158/1078-0432.CCR-24-0562.